Global Competition and Biotechnology Industry: A Review
The biotechnology industry is a relatively new a distinct field that involve using living organism to produce desired product. This industry includes firms that develop, manufacture, and market pharmaceutical products, agricultural products, environmental control product, e.t.c. based on advanced biotechnology research. Although the growth in the global biotechnology industry neared double digits the past two years, the threat of entry into the market is weak due to high barriers to entry. However, because of the ease and low-cost production using biotechnology, it has increased competition in some product. Leading European nations with strong biotech sectors such as the UK and Germany are investing heavily in regenerative medicine (RM), seeking competitive advantage in this emerging sector. However, in the broader biopharmaceutical sector the European Union (EU) is outperformed by the US on all metrics, reflecting longstanding problems: limited venture capital finance, a fragmented patent system, and relatively weak relations between academia and industry. The current global downturn has exacerbated these difficulties. The crisis comes at a time when the European Union is reframing its approach to the governance of innovation and renewing its commitment to the goal of making Europe the leading player in the global knowledge economy.